ENOV Stock Analysis: Enovis | NYSE
Medical Devices | NYSE, USA | Market Cap: 1.295m USD | 12M Return: -28.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.9M
EPS Trend: 8.6%
Qual. Beats: 0
Rev. Trend: 97.4%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Enovis Corporation (NYSE: ENOV) is a U.S.-based medical technology company founded in 1995 and headquartered in Wilmington, Delaware. The company, formerly known as Colfax Corporation, operates through two main segments: Prevention and Recovery, which provides orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems, compression garments, electrical stimulators for pain management, and physical therapy products; and Reconstructive, which develops and markets surgical implants, instrumentation, and enabling technologies used in joint replacement, limb reconstruction, and foot, ankle, and extremity procedures.
The company sells to a broad range of healthcare professionals, including orthopedic specialists, surgeons, primary care physicians, physical therapists, podiatrists, chiropractors, and athletic trainers, and distributes its products through independent distributors, direct sales channels, and directly to patients. Enovis operates within the global orthopedic medical device sector, an industry supported by aging populations, rising rates of musculoskeletal conditions, and growing demand for joint replacement and rehabilitation products.
- Reconstructive segment drives growth via hip and knee implant demand
- Prevention and Recovery braces and pain management sales expand steadily
- Margin expansion from operational efficiency and portfolio reshaping efforts
| Net Income: -1.14b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.74 > 1.0 |
| NWC/Revenue: 27.70% < 20% (prev 34.45%; Δ -6.75% < -1%) |
| CFO/TA 0.06 > 3% & CFO 242.8m > Net Income -1.14b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.8m) vs 12m ago 0.0% < -2% |
| Gross Margin: 56.81% > 18% (prev 56.51%; Δ 0.30% > 0.5%) |
| Asset Turnover: 52.33% > 50% (prev 44.11%; Δ 8.23% > 0%) |
| Interest Coverage Ratio: -18.39 > 6 (EBIT TTM -1.04b / Interest Expense TTM 56.8m) |
| A: 0.16 (Total Current Assets 1.24b - Total Current Liabilities 608.7m) / Total Assets 3.83b |
| B: -0.39 (Retained Earnings -1.48b / Total Assets 3.83b) |
| C: -0.24 (EBIT TTM -1.04b / Avg Total Assets 4.35b) |
| D: 0.63 (Book Value of Equity 1.48b / Total Liabilities 2.35b) |
| Altman-Z'' = -1.13 = CCC |
| DSRI: 0.96 (Receivables 444.2m/435.6m, Revenue 2.28b/2.15b) |
| GMI: 0.99 (GM 56.51% / 56.81%) |
| AQI: 0.80 (AQ_t 0.52 / AQ_t-1 0.65) |
| SGI: 1.06 (Revenue 2.28b / 2.15b) |
| TATA: -0.36 (NI -1.14b - CFO 242.8m) / TA 3.83b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 25.75 with a total of 626,053 shares traded. Over the past week, the price has changed by +14.44%, over one month by +17.21%, over three months by +5.45% and over the past year by -28.35%.
Current recommended Stop Loss: 22.40 (which is 13% or 2 ATR below the current price).
Enovis has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy ENOV.
- StrongBuy: 7
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42.3 | 64.3% |
P/E Forward = 6.0976
P/S = 0.5685
P/B = 0.8769
P/EG = 3.4477
Revenue TTM = 2.28b USD
EBIT TTM = -1.04b USD
EBITDA TTM = -748.3m USD
Long Term Debt = 1.29b USD (from longTermDebt, last quarter)
Short Term Debt = 60.2m USD (from shortTermDebt, last quarter)
Debt = 1.50b USD (from shortLongTermDebtTotal, last quarter) + Leases 84.6m
Net Debt = 1.46b USD (calculated: Debt 1.50b - CCE 33.1m)
Enterprise Value = 2.76b USD (1.30b + Debt 1.50b - CCE 33.1m)
Interest Coverage Ratio = -18.39 (Ebit TTM -1.04b / Interest Expense TTM 56.8m)
EV/FCF = 76.75x (Enterprise Value 2.76b / FCF TTM 35.9m)
FCF Yield = 1.30% (FCF TTM 35.9m / Enterprise Value 2.76b)
FCF Margin = 1.58% (FCF TTM 35.9m / Revenue TTM 2.28b)
Net Margin = -49.91% (Net Income TTM -1.14b / Revenue TTM 2.28b)
Gross Margin = 56.81% ((Revenue TTM 2.28b - Cost of Revenue TTM 983.9m) / Revenue TTM)
Gross Margin QoQ = 54.92% (prev 60.69%)
Tobins Q-Ratio = 0.72 (Enterprise Value 2.76b / Total Assets 3.83b)
Interest Expense / Debt = 3.80% (Interest Expense 56.8m / Debt 1.50b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -825.3m (EBIT -1.04b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.04 (Total Current Assets 1.24b / Total Current Liabilities 608.7m)
Debt / Equity = 1.01 (Debt 1.50b / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = -1.95 (negative EBITDA) (Net Debt 1.46b / EBITDA -748.3m)
Debt / FCF = 40.70 (Net Debt 1.46b / FCF TTM 35.9m)
Total Stockholder Equity = 1.89b (last 4 quarters mean from totalStockholderEquity)
RoA = -26.12% (Net Income -1.14b / Total Assets 3.83b)
RoE = -60.13% (Net Income TTM -1.14b / Total Stockholder Equity 1.89b)
RoCE = -32.83% (EBIT -1.04b / Capital Employed (Equity 1.89b + L.T.Debt 1.29b))
RoIC = -25.39% (negative operating profit) (NOPAT -825.3m / Invested Capital 3.25b)
WACC = 6.74% (E(1.30b)/V(2.79b) * Re(11.05%) + D(1.50b)/V(2.79b) * Rd(3.80%) * (1-Tc(0.21)))
Discount Rate = 11.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 62.99 | Cagr: 1.77%
[DCF] Terminal Value 75.44% ; FCFF base≈35.9m ; Y1≈36.1m ; Y5≈38.2m
[DCF] Fair Price = N/A (negative equity: EV 594.3m - Net Debt 1.46b = -867.7m; debt exceeds intrinsic value)
EPS Correlation: 8.56 | EPS CAGR: 5.26% | SUE: 0.10 | # QB: 0
Revenue Correlation: 97.43 | Revenue CAGR: 14.43% | SUE: 2.54 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.85 | Chg30d=-0.07% | Revisions=-58% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.84 | Chg30d=-0.30% | Revisions=-8% | Analysts=11
EPS current Year (2026-12-31): EPS=3.65 | Chg30d=+0.03% | Revisions=+31% | GrowthEPS=+10.6% | GrowthRev=+4.3%
EPS next Year (2027-12-31): EPS=4.08 | Chg30d=+0.17% | Revisions=+62% | GrowthEPS=+11.7% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: +10% (up=21, down=17)